Prediction of 12-Week Remission by Psychopharmacological Treatment Step in Patients With Depressive Disorders

被引:0
|
作者
Jin, Yun-Tae [1 ]
Kim, Ha-Yeon [1 ]
Jhon, Min [1 ]
Kim, Ju-Wan [1 ]
Kang, Hee-Ju [1 ]
Lee, Ju-Yeon [1 ]
Kim, Sung-Wan [1 ]
Shin, Il-Seon [1 ]
Kim, Jae-Min [1 ,2 ]
机构
[1] Chonnam Natl Univ, Dept Psychiat, Med Sch, Gwangju, South Korea
[2] Chonnam Natl Univ, Dept Psychiat, Med Sch, 160 Baekseo ro, Gwangju 61469, South Korea
基金
新加坡国家研究基金会;
关键词
Depression; Remission; Prediction; Pharmacotherapy; Treatment step; MEASUREMENT-BASED CARE; TREATMENT OUTCOMES; SCALE; EVENTS;
D O I
10.30773/pi.2022.0160
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective To investigate the predictors of remission by 4 treatment steps in depressive outpatients receiving 12-week psychopharma-cotherapy. Methods Patients were consecutively recruited at a university hospital in South Korea from March 2012 to April 2017. At baseline, 1,262 patients were evaluated for sociodemographic and clinical data including assessments scales, and were received antidepressant mono -therapy. For patients with an insufficient response or uncomfortable side effects, next treatment steps (1, 2, 3, and 4) with alternative strategies (switching, augmentation, combination, and mixtures of these approaches) were administered considering measurements and patient preference at every 3 weeks in the acute treatment phase (3, 6, 9, and 12 weeks). Remission was defined as a Hamilton Depres-sion Rating Scale score of <= 7. Results In the multi-variate logistic regression analyses, remission was predicted by higher functional levels in patients received Step 1 and 2 treatment; by lower life stressors in Step 1; by higher social support in Step 3 and 4; and by lower suicidality in Step 1-3. Conclusion Differential associations were found between symptoms or functions and treatment steps, which suggested that multi -fac-eted evaluations at baseline could predict remission by treatment steps. Psychiatry Investig 2022;19(10):866-871
引用
收藏
页码:866 / +
页数:8
相关论文
共 50 条
  • [1] Associations of Serum Serotonin Levels with 12-week and 12-month Remission in Patients with Depressive Disorders
    Choi, Wonsuk
    Kang, Hee-Ju
    Kim, Ju-Wan
    Kim, Hee Kyung
    Kang, Ho-Cheol
    Lee, Ju-Yeon
    Kim, Sung-Wan
    Stewart, Robert
    Kim, Jae-Min
    [J]. CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2022, 20 (02) : 248 - 258
  • [2] Predictors of 12-week remission in a nationwide cohort of people with depressive disorders: the CRESCEND study
    Kim, Jae-Min
    Kim, Sung-Wan
    Stewart, Robert
    Kim, Seon-Young
    Yoon, Jin-Sang
    Jung, Sung-Won
    Lee, Min-Soo
    Yim, Hyeon-Woo
    Jun, Tae-Youn
    [J]. HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2011, 26 (01) : 41 - 50
  • [3] Physical comorbidity and 12-week treatment outcomes in Korean patients with depressive disorders: The CRESCEND study
    Kim, Jae-Min
    Stewart, Robert
    Bae, Kyung-Yeol
    Yang, Su-Jin
    Yoon, Jin-Sang
    Jung, Sung-Won
    Lee, Min-Soo
    Yim, Hyeon-Woo
    Jun, Tae-Youn
    [J]. JOURNAL OF PSYCHOSOMATIC RESEARCH, 2011, 71 (05) : 311 - 318
  • [4] Prospective associations of multimodal serum biomarkers with 12-week and 12-month remission in patients with depressive disorders receiving stepwise psychopharmacotherapy
    Kim, Jae-Min
    Kang, Hee-Ju
    Kim, Ju-Wan
    Jhon, Min
    Choi, Wonsuk
    Lee, Ju-Yeon
    Kim, Sung-Wan
    Shin, Il-Seon
    Kim, Min-Gon
    Stewart, Robert
    [J]. BRAIN BEHAVIOR AND IMMUNITY, 2022, 104 : 65 - 73
  • [5] Agomelatine for the Treatment of Patients with Fibromyalgia and Depressive Symptomatology: An Uncontrolled, 12-Week, Pilot Study
    Calandre, E. P.
    Slim, M.
    Garcia-Leiva, J. M.
    Rodriguez-Lopez, C. M.
    Torres, P.
    Rico-Villademoros, F.
    [J]. PHARMACOPSYCHIATRY, 2014, 47 (02) : 67 - 72
  • [6] Comorbid physical disorders and 12 week treatment outcomes in Korean patients with depressive disorders
    Yoo, J. A.
    Kim, J. A.
    Yang, S. J.
    Kim, S. W.
    Shin, I. S.
    Yoon, J. S.
    Kim, J. B.
    Lee, M. S.
    Lim, H. W.
    Jun, T. Y.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2010, 20 : S337 - S337
  • [7] Patients with functional gastrointestinal disorders benefit from a 12-week multidisciplinary integrated treatment approach to reduce anxiety and depressive symptoms
    Bray, N.
    Koloski, N.
    Jones, M.
    Do, A.
    Talley, N.
    Billin, A.
    Bettens, G.
    Mcallister, S.
    Pang, S.
    Arthur, L.
    Campus, J.
    Chao, C.
    Catague, R.
    Whaley, A.
    Macdonald, G.
    Holtmann, G.
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 : 178 - 178
  • [8] Interaction effect of serum serotonin level and age on the 12-week pharmacotherapeutic response in patients with depressive disorders
    Choi, Wonsuk
    Kim, Ju-Wan
    Kang, Hee-Ju
    Kim, Hee Kyung
    Kang, Ho-Cheol
    Lee, Ju-Yeon
    Kim, Sung-Wan
    Stewart, Robert
    Kim, Jae-Min
    [J]. SCIENTIFIC REPORTS, 2021, 11 (01)
  • [9] Interaction effect of serum serotonin level and age on the 12-week pharmacotherapeutic response in patients with depressive disorders
    Wonsuk Choi
    Ju-Wan Kim
    Hee-Ju Kang
    Hee Kyung Kim
    Ho-Cheol Kang
    Ju-Yeon Lee
    Sung-Wan Kim
    Robert Stewart
    Jae-Min Kim
    [J]. Scientific Reports, 11
  • [10] Synergistic effects of resilience and serum ghrelin levels on the 12-week pharmacotherapeutic response in patients with depressive disorders
    Choi, Wonsuk
    Kim, Ju-Wan
    Kang, Hee-Ju
    Kim, Hee Kyung
    Kang, Ho-Cheol
    Lee, Ju-Yeon
    Kim, Sung-Wan
    Stewart, Robert
    Kim, Jae-Min
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2021, 295 : 1489 - 1493